39.90
+2.05%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gentian Diagnostics A
Its shares trade on Oslo Børs under the ticker GENT.OL. It has been listed since 14 December 2016. In the fiscal year to 31 December 2025, it reported revenue of NOK 176.5m and net income of NOK 13.3m. At that date it held total assets of NOK 258.5m and shareholders' equity of NOK 205.0m.
Gentian Diagnostics ASA is a medical diagnostics company, which engages in the design, development, and manufacture of biochemical reagents and materials for use in medical diagnostics and research. The company is headquartered in Moss, Ostfold. The company went IPO on 2016-12-14. The firm develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The firm is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 14 Dec 2016
- Employees
- 55
- Website
- gentian.com ↗
Leadership
Pay as last reported
- Ms. Hilja IbertChairman of the Board
- Mr. Njaal KindChief Financial Officer, Chief Operating Officer, since 2025
- Mr. Frank FrantzenChief Technology Officer
- Ms. Ingrid AkayDirector
- Ms. Kjersti GrimsrudDirector
- Mr. Espen JorgensenDirector
- Mr. Tomas KramarDirector
- Ms. Kari KrogstadDirector
- Ms. Monika NeumanDirector
- Ms. Susanne StuffersDirector
- Mr. Fredrik ThoresenDirector
- Mr. Runar VatneDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gentian Diagnostics ASA develops IVD products for global diagnostics markets including Sweden, USA, and China.
- The company's product portfolio includes Calprotectin Immunoassay and Cystatin C for clinical chemistry analysers.
- Gentian Diagnostics ASA employs 55 full-time employees in Moss, Norway, focusing on medical diagnostics.
Weaknesses
- Gentian Diagnostics ASA has pre-launch products like NT-proBNP and SARS-CoV-2 Ab in development.
- The company's product range is limited to specific diagnostic markers such as Calprotectin and Cystatin C.
- Gentian Diagnostics ASA operates with a small team of 55 employees in Moss, Norway.
Opportunities
- Gentian Diagnostics ASA can expand its product line with pre-launch items like NT-proBNP and SARS-CoV-2 Ab.
- The global diagnostics market offers growth potential for IVD products in human and veterinary sectors.
- Gentian Diagnostics ASA serves markets in Sweden, USA, and China with existing sales offices.
Threats
- Gentian Diagnostics ASA faces competition from established IVD manufacturers in the global market.
- The company's pre-launch products require regulatory approval before market entry.
- Gentian Diagnostics ASA's small size may limit its ability to compete with larger diagnostics firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.